Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK... see more

Recent & Breaking News (NDAQ:CRIS)

Curis Announces Proposed Public Offering of Common Stock

PR Newswire December 8, 2020

Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

PR Newswire December 8, 2020

Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

PR Newswire December 7, 2020

Curis to Host Virtual Event to Discuss CA-4948 Clinical Data

PR Newswire December 2, 2020

Curis Reports Third Quarter 2020 Financial Results

PR Newswire November 10, 2020

Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent

PR Newswire November 10, 2020

Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition

PR Newswire November 4, 2020

Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference

PR Newswire November 4, 2020

Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020

PR Newswire November 2, 2020

Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies

PR Newswire October 21, 2020

Curis Announces Abstract for CI-8993 Accepted for Presentation at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting

PR Newswire October 14, 2020

Curis to Present at Upcoming Investor Conferences

PR Newswire September 10, 2020

Curis Reports Second Quarter 2020 Financial Results

PR Newswire August 4, 2020

Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020

PR Newswire July 28, 2020

Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

PR Newswire July 7, 2020

Curis Announces $17.5 Million Registered Direct Offering

PR Newswire June 11, 2020

Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

PR Newswire June 10, 2020

Curis Reports First Quarter 2020 Financial Results

PR Newswire May 12, 2020

Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

PR Newswire May 5, 2020

Curis to Present at 19th Annual Needham Virtual Healthcare Conference

PR Newswire April 7, 2020